The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial

समान संसाधन

• Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
  द्वारा: Borthwick, N, और अन्य
  प्रकाशित: (2013)
• Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
  द्वारा: Ondondo, B, और अन्य
  प्रकाशित: (2013)
• Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
  द्वारा: Ondondo, B, और अन्य
  प्रकाशित: (2013)
• Targeting HIV-1 Where It Hurts
  द्वारा: Ahmed, T, और अन्य
  प्रकाशित: (2013)
• Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
  द्वारा: Hancock, G, और अन्य
  प्रकाशित: (2017)